The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age (vol 18, e13236, 2024)

초록

In the article, there were errors in the affiliations of Laura Helman and John H. Powers III. Their correct affiliations are shown below. Desmond Curran 1 |Sean Matthews 2|Eliazar Sabater Cabrera 1 |Silvia Narejos Pérez 3|Lina Pérez Breva 4|Mika Rämet 5|Laura Helman 6|Dae Won Park 7|Tino F. Schwarz 8|Isabel Maria Galan Melendez 9|Axel Schaefer 10|Nathalie Roy 11|Brigitte Stephan 12|Daniel Molnar 1 |Lusine Kostanyan 1 |John H. Powers III 13|Veronica Hulstrøm 1|Members of the AReSVi-006 Study Group 1GSK, Wavre, Belgium 2 Freelance c/o GSK, Wavre, Belgium 3 CAP Centelles, Barcelona, Spain 4 Vaccine Research, FISABIO-Public Health, Valencia, Spain 5 Finnish Vaccine Research, Tampere, Finland 6 MOC Research, Mishawaka, Indiana, USA 7 Korea University Ansan Hospital, Ansan, Republic of Korea 8 Institute of Laboratory Medicine and Vaccination Centre, Klinikum Würzburg Mitte, Würzburg, Germany 9 Hospital Universitario Fundacion Alcorcon, Madrid, Spain 10 Medizentrum Essen Borbeck, Essen, Germany 11 Medicor Research, Greater Sudbury, Canada 12 SGS proDERM, Schenefeld, Germany 13 Department of Clinical Medicine, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia, USA We apologize for this error. © 2025 The Author(s). Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.